Concepedia

Simrati Kaul

SK

9

Publications

1.1K

Citations

9

H-Index

2007

Active since

Affiliations

Janssen (United States)(Current)

Janssen Scientific Affairs (United States)

Memorial Sloan Kettering Cancer Center

Charité - Universitätsmedizin Berlin

Cleveland Clinic

Simrati Kaul is an author at Janssen (United States) specializing in urology, clinical microbiology, and medicine.

ORCID

Top concepts

Publications per year

2007–2023

9

Publications

9

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Alok A. Khorana, Gerald A. Soff, Ajay K. Kakkar et al. · New England Journal of Medicine · 2019 · 683 citations · Full text

A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis

Janet Peterson, Simrati Kaul, ‏Mohammed ‏Khashab et al. · Urology · 2008 · 181 citations

, , +8

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis

Howard Klausner, Patricia D. Brown, Janet Peterson et al. · Current Medical Research and Opinion · 2007 · 82 citations

Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study

C. Michael Gibson, Steven R. Steinhubl, Dhanunjaya Lakkireddy et al. · American Heart Journal · 2023 · 39 citations · Full text

Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study

Saroj Vadhan‐Raj, Mairéad G. McNamara, Marino Venerito et al. · Cancer Medicine · 2020 · 37 citations · Full text

Rows per page

1–5 of 9